Intra-Cellular Therapies Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Intra-Cellular Therapies stock.
View analyst ratings for Intra-Cellular Therapies or view top-rated stocks.

Wall Street analysts have given Intra-Cellular Therapies a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Intra-Cellular Therapies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Intra-Cellular Therapies is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Intra-Cellular Therapies.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) released its earnings results on Sunday, May, 9th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.81) by $0.16. The biopharmaceutical company earned $15.88 million during the quarter, compared to analyst estimates of $15.74 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 39.41% and a negative net margin of 617.78%.
View Intra-Cellular Therapies' earnings history.

Intra-Cellular Therapies' stock was trading at $17.77 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ITCI stock has increased by 143.0% and is now trading at $43.18.
View which stocks have been most impacted by COVID-19.

7 brokers have issued 12 month price targets for Intra-Cellular Therapies' shares. Their forecasts range from $36.00 to $70.00. On average, they anticipate Intra-Cellular Therapies' stock price to reach $47.43 in the next year. This suggests a possible upside of 9.8% from the stock's current price.
View analysts' price targets for Intra-Cellular Therapies or view top-rated stocks among Wall Street analysts.

Some companies that are related to Intra-Cellular Therapies include Grifols (GRFS), Dr. Reddy's Laboratories (RDY), CureVac (CVAC), Maravai LifeSciences (MRVI), Ono Pharmaceutical (OPHLF), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), BridgeBio Pharma (BBIO), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), United Therapeutics (UTHR), Ascendis Pharma A/S (ASND), Evotec (EVTCY) and Ultragenyx Pharmaceutical (RARE).
View all of ITCI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Intra-Cellular Therapies' stock is owned by many different retail and institutional investors. Top institutional shareholders include Wasatch Advisors Inc. (8.04%), BlackRock Inc. (7.58%), Lord Abbett & CO. LLC (2.61%), Samlyn Capital LLC (1.69%), Schroder Investment Management Group (1.63%) and TimesSquare Capital Management LLC (1.51%). Company insiders that own Intra-Cellular Therapies stock include Andrew Satlin, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Mark Neumann, Michael Halstead, Sharon Mates and Suresh K Durgam.
View institutional ownership trends for Intra-Cellular Therapies.

ITCI stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Dimensional Fund Advisors LP, Samlyn Capital LLC, Clearbridge Investments LLC, Tekla Capital Management LLC, Northern Trust Corp, SG Americas Securities LLC, and JPMorgan Chase & Co.. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Mark Neumann, Michael Halstead, Sharon Mates, and Suresh K Durgam.
View insider buying and selling activity for Intra-Cellular Therapies or view top insider-selling stocks.

ITCI stock was acquired by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Franklin Resources Inc., TimesSquare Capital Management LLC, BlackRock Inc., Goldman Sachs Group Inc., Wasatch Advisors Inc., Nicholas Investment Partners LP, and Suvretta Capital Management LLC.
View insider buying and selling activity for Intra-Cellular Therapies or or view top insider-buying stocks.

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ITCI stock can currently be purchased for approximately $43.18.

Intra-Cellular Therapies has a market capitalization of $3.51 billion and generates $22.81 million in revenue each year. The biopharmaceutical company earns $-227,010,000.00 in net income (profit) each year or ($3.23) on an earnings per share basis.

Intra-Cellular Therapies employs 383 workers across the globe.

The official website for Intra-Cellular Therapies is www.intracellulartherapies.com.

Intra-Cellular Therapies is headquartered at 430 EAST 29TH STREET, NEW YORK NY, 10016.

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected]